The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients

Prior treatment

• Previous history of gastrointestinal ulcer bleeding;
• Long-term use of PPI and H2 receptor inhibitors in the past;
• Those who are taking anti-coagulation drugs such as vitamin K antagonists (warfarin) ,factor X or factor II inhibitors;
• Recently received fibrinolytic therapy (using fibrin-specific drugs within 24 hours before randomization, or using non-fibrin-specific drugs within 48 hours before randomization);
• Recently accepted (within 30 days before randomization) or planned to undergo coronary artery bypass grafting (CABG);
• Have taken antibiotics and other drugs that affect the flora in the stomach within the past month;
• Patients who participated in clinical trials of other drugs or are participating in clinical studies of other new drugs within 30 days before enrollment;

Other illness

• Combining active bleeding or coagulation dysfunction (indicator);
• Complicated with hemorrhagic stroke, intracranial tumor, arteriovenous malformation or aneurysm;
• A history of allergy to aspirin, clopidogrel, ticagrelor, pantoprazole, penicillin and other test drugs;
• With malignant tumors and other diseases, the expected survival time is less than 1 year;
• Complicated with mental illness or severe neurosis;

Lab values

• In patients with liver and kidney disease, serum creatinine is greater than 150 μmol/L, GFR \<60ml/min/1.73m2, alanine aminotransferase and aspartate aminotransferase increase ≥3 times from the normal value;
• Anemia (adult male hemoglobin less than 120 g/L or red blood cells less than 4×10\^12/L,adult female hemoglobin less than 105 g/L or red blood cells less than 3.5×10\^12/L);

Age

• Pregnancy or breastfeeding women and subjects of childbearing age who do not want to take contraceptive measures;

Other

• Complicated with gastroesophageal varices, or after gastrectomy;
• Systemic glucocorticoid application;
• Can't express subjective discomfort symptoms;
• The investigator decides that it is not suitable to participate in this research.

• Patients with ACS and PCI treatment and postoperative DAPT ≥ 6 months;
• Hp infection is positive;
• Age ≥18 years old;
• The patient himself or his authorized client signs the subject's consent.